Endocyte Announces Third Quarter 2012 Earnings Conference Call

        Print
| Source: Endocyte, Inc.

WEST LAFAYETTE, Ind., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company will host a conference call on Thursday, Nov. 1, at 4:30 p.m. EDT, to discuss its third quarter financial results and provide an operational update.

Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investor Relations section of the Company's website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).

A replay of the call will be available beginning at 7:30 p.m. EDT on Nov. 1, until midnight EDT on Nov. 8, 2012. To access the replay, please dial (855) 859-2056 (U.S./Canada) or (404) 537-3406 (International) and reference the conference 58062954. Additionally, the webcast will be recorded and available on the Company's website for two weeks following the call.

About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

Paul Cox, Stern Investor Relations, Inc., (212) 362-1200,


Martina Schwarzkopf, Ph.D., Russo Partners, (212) 845-4292,


Tony Russo, Ph.D., Russo Partners, (212) 845-4251,